Deltace

N/A

Report date: 2024/08/15 09:20:06

Base Information

Drug NameDeltace

Drug Alias NameDeltacel/KB-GDTKB-GDTGamma delta chimeric antigen receptor T-cell therapy(Kiromic Biopharma)DeltacelGamma delta CAR T-cell therapy (Kiromic Biopharma) +[7]

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsUpdating

Therapy Area/IndicationsBone metastasesSolid tumoursCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesKiromic Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesKiromic Biopharma Inc

Inactive CompaniesN/A

Active IndicationsBone metastasesSolid tumoursCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A